Child Nutrition Disorders
Conditions
Brief summary
This will be cohort study design with both qualitative and quantitative methods of data collection. The investigators are aiming to study 64 HIV positive children as healthy controls either initiating ART or already on ART and 86 malnourished HIV infected children on ART or naïve initiating ART and RUTF aged between 6 months to 12 years. Primary carers will be asked to provide informed consent whereby the children and primary carers will be enrolled into the study and followed up for 12 weeks.
Detailed description
BACKGROUND: Malnutrition and Human Immunodeficiency Virus (HIV) infection are intimately linked and present a serious health challenge in Africa. Approximately 30-50% of children in Uganda with severe acute malnutrition (SAM) are HIV infected. Studies on nutrition as a determinant of immune response and drug metabolism in malnourished children are unknown. GAP: Clinicians have noted that certain patients deteriorate after starting ART and nutritional supplementation despite viralogical suppression and immunological improvement with a paradoxical emergence of certain opportunistic infections, electrolyte derangement and malnutrition hence IRIS or re-feeding syndrome (RF). There is paucity of data on nutrition as a determinant of immune and pharmacological response amongst HIV infected malnourished children despite malnutrition being common. HYPOTHESIS: Well-nourished HIV infected children ART naïve or experienced will have a better nutritional, clinical, immunological and pharmacological outcome than malnourished children ART naïve or experienced. METHODS: A cohort design studying 75 malnourished HIV infected children on ART and RUTF comparing them to 75 well-nourished children ART naive or experienced aged between 6 months to 12 years after primary carers have provided informed consent will be enrolled into the study and followed up for 12 weeks. IMPACT: This study will endeavor to provide appropriate information that will enhance the management of malnourished HIV infected children in the context of both ART and RUTF and their impact on immune response and drug metabolism. The study will also generate other research questions that need to be addressed in order to optimize HIV services amongst malnourished children.
Interventions
DIETARY_SUPPLEMENTRUTF
This is ready-to-use-therapeutic-food
Sponsors
University of Dublin, Trinity College
Infectious Diseases Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 12 Years
Healthy volunteers
No
Inclusion criteria
* HIV-infected children aged 6 months to 12 years, including Well Nourished (WN), Moderately Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) patients initiating on ART within 2 weeks, whose carer is aged ≥18 years and has provided informed consent. * Malnourished HIV-infected children aged 6 months to 12 years stabilized on ART for at least 6 months and initiating on RUTF, whose carer is aged ≥18 years and has provided informed consent.
Exclusion criteria
1. Previous enrollment in a nutritional therapeutic program in the last 3 months 2. Children involved in an on-going nutrition study 3. Children who have previously received the tuberculin skin test (TST) or mantoux or purified protein derivative (PPD) in the last 3 months. 4. Children with clinically suspected or confirmed malignancy 5. Children exhibiting any specific food intolerance 6. Children who are vomiting profusely (over 3 times daily) 7. Children living outside 50 km radius from Infectious Diseases Institute at Mulago, Kampala 8. Children whose carers do not want to disclose their home address. 9. Children whose cause of malnutrition is compounded by congenital malformations, chromosomal disorders, metabolic disorders, congenital immune disorders, cerebral palsy 10. Children with a severe disability limiting the possibility of investigations 11. Children who plan to leave the catchment area in the next 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in numbers of circulating immune cell population and their capacity to release cytokines | 12 weeks | Immune response |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of Immune reconstitution inflammatory syndrome (IRIS) | 12 weeks | Episodes of Opportunistic infections - Clinical outcomes |
| Occurrence of re-feeding syndrome | 12 weeks | Episodes of Opportunistic infections - Clinical outcomes |
| Pharmacological: Cmax | 12 weeks | Cmax of Non-nucleotide reverse - transcriptase inhibitors (NNRTI) and Protease Inhibitors(PIs) at 0weeks, 6weeks,12weeks |
| Pharmacological: AUC | 12 weeks | Area Under Curve (AUC) Time Frame: 0weeks, 6weeks, 12weeks for nevirapine and lopinvir/retonavir |
| Number of participants with adverse events | 12 weeks | Pharmacological: Number of participants with adverse events |
Countries
Uganda
Contacts
Primary ContactJudy Orikiiriza, MMED
Backup ContactAllen M Mukhwana, MBA
Outcome results
None listed